HIGHLIGHTS
- who: Lin Qi from the Medical University of Vienna, Austria have published the Article: Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis, in the Journal: (JOURNAL) of 31/Oct/2021
- what: Seven studies were published within the past 5 years , which indicated that this study was innovative and the immune checkpoint inhibitors were developed rapidly in cervical cancer treatment. The results of this study showed that the median OS of pembrolizumab group was 10.23 months, the median PFS was 4.27 months, the ORR was 15 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.